This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
OncoMed Pharmaceuticals (OMED) Q3 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
OncoMed (OMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OncoMed Pharmaceuticals (OMED) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
OncoMed (OMED) delivered earnings and revenue surprises of 56.52% and -8.28%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y
by Zacks Equity Research
Acorda's (ACOR) earnings and revenues lag estimates in Q1. The company reiterates its 2018 outlook for the key drug Ampyra.
Allergan (AGN) Q1 Earnings Beat Estimates, Sales Up Y/Y
by Zacks Equity Research
Allergan's (AGN) first-quarter 2018 earnings surpass estimates with revenues also marginally beating the same. Moreover, the company ups its adjusted earnings and sales view for the full year.
Pick 3 Biotech Money-Spinning Bets Amid Market Instability
by Debapriya Chakraborty
The drugs/biotech sector has been down since the past month, reeling under broader market pressures. Only a few good stocks however, remain out of this rut.
Can The Uptrend Continue for OncoMed Pharmaceuticals (OMED)?
by Zacks Equity Research
Investors certainly have to be happy with OncoMed Pharmaceuticals, Inc. (OMED) and its short term performance
Here's Why OncoMed Pharmaceuticals (OMED) Stock Fell Today
by Joseph Lu
Shares of OncoMed Pharmaceuticals Inc. (OMED) closed the day down 3.74% to $3.86 per share. The plunge came after both JMP (JMP) and Piper Jaffray (PJC) downgraded the company???s rating.
OncoMed Cancer Candidate Fails Trial, Bayer Opts Out of Deal
by Zacks Equity Research
It was a bad day for OncoMed Pharmaceuticals, Inc. (OMED) as it suffered two setbacks.
Are Options Traders Betting on a Big Move in OncoMed Pharmaceuticals (OMED) Stock?
by Zacks Equity Research
OncoMed Pharmaceuticals (OMED) warrants investors' attention based on moves in the options market lately.
Are Options Traders Betting on a Big Move in OncoMed (OMED) Stock?
by Amanda Priyanka Gomes
Options traders are pricing in a big move for OncoMed (OMED) shares as it has huge implied volatility.